Back

Circulating angiopoietin-like protein 3 levels and subsequent cardiovascular outcomes in patients with coronary artery disease

31 August 2026 (09:15 - 09:45)
Organised by: Logo
Congress Presentation Part of: Secondary prevention in coronary artery disease Secondary Prevention ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mr Shuhei Fujita

National Cerebral & Cardiovascular Center, Suita (Japan)

3 More presentations in this session

Presentation thumbnail
Empowering the cardiovascular care team in "pillars of protection: adult immunizations in heart disease patients": a global educational intervention with focus on cardiologist leadership
Doctor S. Voorn (NL)
Presentation thumbnail
Implementation gaps in secondary prevention between coronary and cerebrovascular disease: a multicenter real-world study
Doctor A. Young (Ciudad Autonoma De Buenos Aires, AR)
Abstract Slides Video
Presentation thumbnail
NLP-based automated detection of coronary artery calcification on routine chest CT: unmet need for guideline-directed LDL reduction
Doctor O. Paul (Stuttgart, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Secondary prevention in coronary artery disease

The Event

Event poster

ESC Congress 2026

31 August 2026 09:15 CET
You may be interested in
thumbnail
Congress Presentation
Angiopoietin-like protein 4 identifies residual risk for atherothrombotic events in stable post-acute coronary syndrome patients: insights from the SPUM-ACS study
30 August 2026
thumbnail
Congress Presentation
Genetic inhibition of angiopoietin-like protein 3, 4, and 8 on cardiovascular disease risk
30 August 2025
thumbnail
Congress Presentation
Angioprotein-like 3 and atheroma progression in statin-treated type 2 diabetic patients with coronary artery disease: the pre-specified analysis from the OPTIMAL randomized controlled trial.
30 August 2024
thumbnail
Congress Presentation
Association of Lipoprotein(a) with cardiovascular and all-cause mortality in China: a cohort study based on cardiorenal improvementNT-II
29 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources